Abstract
Acquired mutations in BTK, PLCG2, and BCL2 are associated with resistance to continuous targeted agent therapy in chronic lymphocytic leukemia (CLL). Here, we discuss new evidence that limiting the duration of CLL therapy may prevent the evolution of such resistance mutations, potentially facilitating effective retreatment strategies. See related article by Jain et al., p. 498.
©2023 American Association for Cancer Research.
Publication types
-
Research Support, Non-U.S. Gov't
-
Research Support, N.I.H., Extramural
-
Comment
MeSH terms
-
Agammaglobulinaemia Tyrosine Kinase / genetics
-
Antineoplastic Agents* / pharmacology
-
Antineoplastic Agents* / therapeutic use
-
Drug Resistance, Neoplasm / genetics
-
Humans
-
Leukemia, Lymphocytic, Chronic, B-Cell* / drug therapy
-
Leukemia, Lymphocytic, Chronic, B-Cell* / genetics
-
Mutation
Substances
-
Agammaglobulinaemia Tyrosine Kinase
-
Antineoplastic Agents